Loading...
LRMR logo

Larimar Therapeutics, Inc.Informe acción NasdaqGM:LRMR

Capitalización bursátil US$347.6m
Precio de las acciones
US$3.53
US$15.88
77.8% infravalorado descuento intrínseco
1Y82.9%
7D-13.9%
Valor de la cartera
​
Ver

Larimar Therapeutics, Inc.

Informe acción NasdaqGM:LRMR

Capitalización de mercado: US$347.6m

Larimar Therapeutics (LRMR) Resumen de Acciones

Larimar Therapeutics, Inc, una empresa biotecnológica en fase clínica, se centra en el desarrollo de tratamientos para enfermedades raras utilizando su novedosa plataforma tecnológica de péptidos que penetran en las células. Saber más

Análisis fundamental de LRMR
Puntuación del snowflake
Valoración1/6
Crecimiento futuro5/6
Rendimiento pasado0/6
Salud financiera6/6
Dividendos0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 56.13%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Precio de las acciones muy volátil durante los últimos 3 meses en comparación con el mercado US

Los accionistas han sido diluidos sustancialmente en el último año


LRMR Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Larimar Therapeutics, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Larimar Therapeutics
Precios históricos de las acciones
Precio actual de la acciónUS$3.53
Máximo en las últimas 52 semanasUS$6.42
Mínimo de 52 semanasUS$1.80
Beta0.91
Cambio en 1 mes-26.61%
Variación en 3 meses13.50%
Cambio de 1 año82.90%
Variación en 3 años-3.42%
Variación en 5 años-60.73%
Variación desde la OPV-71.30%

Noticias y actualizaciones recientes

Artículo de análisis • Jan 24

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 16

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Summary Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating. With $175.4m cash runway into Q4-26 and multiple near-term catalysts, LRMR offers asymmetric risk-reward, targeting a 3-5x return if milestones are met. Read the full article on Seeking Alpha

Recent updates

Artículo de análisis • Jan 24

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 16

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Summary Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating. With $175.4m cash runway into Q4-26 and multiple near-term catalysts, LRMR offers asymmetric risk-reward, targeting a 3-5x return if milestones are met. Read the full article on Seeking Alpha
Artículo de análisis • May 28

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 03

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Summary Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025. Accelerated Approval BLA filing of nomlabofusp for patients with Friedreich's Ataxia might be possible 2nd half of 2025 on basis of a surrogate biomarker endpoint of FXN protein levels. Read the full article on Seeking Alpha
Artículo de análisis • Dec 18

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 07

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Summary Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades at reasonable valuations compared to its upside potential. LRMR's favorable Phase 1/2 trial results bolster CTI-1601's approval odds, with a potential Biologics License Application submission by 2H2025. Additionally, CTI-1601 has multiple FDA and EU designations, potentially expediting its development and approval process. Despite competition risks, LRMR's unique approach and sufficient resources make it a speculative "Buy" for investors aware of inherent biotech risks. Read the full article on Seeking Alpha
Artículo de análisis • Aug 09

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 15

Larimar Therapeutics: More Data Still Needed

Summary Larimar Therapeutics' stock has surged 50% after its FA therapy was selected for FDA's START program, aiming for a BLA filing in 2H25. Its lead candidate Nomlabofusp is a protein replacement therapy for Friedreich's ataxia, competing with Biogen's Skyclarys and other potential treatments. Larimar has enough cash to fund operations until 2026, with analyst optimism and a timeline to potentially beat competitors to the market. Can the recent rally in the shares continue? A full investment analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 31

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $2.06 billion by 2030. Interim data from the ongoing phase 2 open-label study, using nomlabofusp for the treatment of patients with Friedreich's Ataxia, expected Q4 of 2024. Nomlabofusp for the treatment of patients with Friedreich's Ataxia selected as part of the FDA pilot program known as START, which is intended to accelerate the development of drugs that target rare unmet medical needs. Read the full article on Seeking Alpha
Artículo de análisis • Nov 13

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • May 19

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Artículo de análisis • Feb 02

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 20

Laramar Therapeutics issued patent for lead pipeline candidate

Larimar Therapeutics (NASDAQ:LRMR) has been granted a composition of matter patent covering CTI-1601, its lead pipeline candidate for Friedreich’s ataxia. The patent provides coverage through at least July 2040. CTI-1601, currently in phase 1, has Fast Track and Orphan Drug designation from the US FDA. The company plans to begin a phase 2 trial for CTI-1601 by the end of the year. Seeking Alpha's Quant Rating views Larimar (LRMR) as a strong buy with high marks for momentum and revisions.
Seeking Alpha • Sep 14

Larimar Therapeutics prices ~$70M stock offering

Larimar Therapeutics (NASDAQ:LRMR) has priced of an underwritten offering of 22,225,000 shares of common stock at $3.15 per share. Underwriters have been granted a 30-day overallotment option to purchase up to 3,333,750 additional shares of common stock at the offering price. Gross proceeds to Larimar (LRMR) are expected to be ~$70M. The offering is expected to close around Sep 16, 2022. The biotech company also received FDA clearance to initiate the 25mg cohort of a Phase 2 Dose exploration trial of its lead compound, CTI-1601, in Friedreich's ataxia patients. It plans to begin the Phase 2 trial in Q4 2022, with top-line data expected in 2H 2023. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia who are unable to produce enough of this essential protein. LRMR shares have gained 2% pre-market on the news
Artículo de análisis • Sep 02

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

Larimar Therapeutics GAAP EPS of -$0.47

Larimar Therapeutics press release (NASDAQ:LRMR): Q2 GAAP EPS of -$0.47. Cash and marketable debt securities at June 30, 2022 of $54.9 million provides projected cash runway through the third quarter of 2023
Artículo de análisis • Mar 21

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Dec 18

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Feb 08

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Rentabilidad de los accionistas

LRMRUS BiotechsMercado US
7D-13.9%-3.0%-0.3%
1Y82.9%32.9%26.7%

Rentabilidad vs. Industria: LRMR superó a la industria US Biotechs, que obtuvo un rendimiento del 32.9% el año pasado.

Rentabilidad vs. Mercado: LRMR superó al mercado US, que obtuvo un rendimiento del 26.7% el año pasado.

Volatilidad de los precios

Is LRMR's price volatile compared to industry and market?
LRMR volatility
LRMR Average Weekly Movement21.8%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Precio estable de las acciones: El precio de las acciones de LRMR ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de LRMR ha aumentado de 16% a 22% en el último año.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
n/a71Carole Ben-Maimonwww.larimartx.com

Larimar Therapeutics, Inc, empresa de biotecnología en fase clínica, se centra en el desarrollo de tratamientos para enfermedades raras utilizando su novedosa plataforma tecnológica de péptidos que penetran en las células. Su principal producto candidato es el CTI-1601, que se encuentra en la fase 2 del ensayo clínico OLE para el tratamiento de la ataxia de Friedreich, una enfermedad rara, progresiva y mortal. La empresa tiene su sede en Bala Cynwyd, Pensilvania.

Resumen de fundamentos de Larimar Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Larimar Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de LRMR
Capitalización bursátilUS$347.60m
Beneficios(TTM)-US$166.00m
Ingresos (TTM)n/a
0.0x
Ratio precio-ventas (PS)
-2.2x
Ratio precio-beneficio (PE)

¿Está LRMR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de LRMR
IngresosUS$0
Coste de los ingresosUS$0
Beneficio brutoUS$0
Otros gastosUS$166.01m
Beneficios-US$166.00m

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-1.59
Margen bruto0.00%
Margen de beneficio neto0.00%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado LRMR a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/20 16:29
Precio de las acciones al final del día2026/05/20 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Larimar Therapeutics, Inc. está cubierta por 16 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Joel BeattyBaird
null nullBaird
Christopher ChenBaird